LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, today announced that preclinical in vitro data related to the characterization of the target associated with its lead monoclonal antibody (ICT-109) will be presented at ASCO. The abstract (#14023) titled “Differential glycan profile of CEACAM5 expressed by small cell lung carcinoma (SCLC) in comparison with colorectal carcinoma,” demonstrated dramatic disparities between the sugar patterns of CEACAM5 on these two cancer types, potentially enabling the development of discerning therapeutics thereby allowing greater safety and efficacy. Furthermore, monoclonal antibody ICT-109 demonstrated the ability to bind to the distinct sugar patterns (glycans) on small cell lung cancer cells with defined specificity and high affinity, potentially making it an ideal candidate for SCLC.
